EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer

Seohyuk Lee, Adriana M Kahn, Mariya Rozenblit, Mridula A George, Cristina Naranjo Ortiz, Maryam B Lustberg iD

Cancer Medicine · 2025-12 · 14 (23)

DOI: 10.1002/cam4.71415 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Medicine, online erschienen am 08.12.2025. Verfasst von Seohyuk Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Medical Oncology, Yale University, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Immunoconjugates, Erb-b2 Receptor Tyrosine Kinases, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HER2‐targeted antibody‐drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2‐targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with > 60 other candidates under ongoing investigation.

Methods

In this report, we provide a narrative review of existing data underlying the current understanding of HER2‐targeted ADC toxicities in breast cancer, highlighting both common and serious adverse events.

Results

When used as an adjuvant or neoadjuvant, first‐ or second‐line agent, alone or in combination with another agent, trastuzumab emtansine has been commonly associated with epistaxis, fatigue, headache, nausea, and pyrexia across several clinical trials. Comparatively, trastuzumab deruxtecan has been commonly associated with alopecia, cytopenias, decreased appetite, fatigue, and gastrointestinal adverse effects.

Conclusion

Despite the demonstrated clinical benefits in breast cancer, diverse systemic and organ‐specific adverse events, including dose‐limiting toxicities, have been reported even at suboptimal therapeutic doses and pose significant barriers to pursuing dose escalations for maximizing therapeutic efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsImmunoconjugatesErb-b2 Receptor Tyrosine KinasesAntineoplastic Agents, ImmunologicalHumansFemaleTrastuzumabAdo-Trastuzumab EmtansineCamptothecin

Stichwörter der Autor:innen

HER2antibody‐drug conjugatebreast cancertoxicity

Substanzen

ImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabAdo-Trastuzumab EmtansineAntineoplastic Agents, ImmunologicalCamptothecinERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Department of Internal Medicine, Section of Medical Oncology, Yale University, New Haven, Connecticut, USA.
  • Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
  • Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
  • Yale Cancer Center, Yale University, New Haven, Connecticut, USA.

ORCID-Profile: Maryam B Lustberg

Zitieren

APA

Lee, S., Kahn, A. M., Rozenblit, M., George, M. A., Naranjo Ortiz, C., & Lustberg, M. B. (2025). HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer. Cancer Medicine, 14(23). https://doi.org/10.1002/cam4.71415

Vancouver

Lee S, Kahn AM, Rozenblit M, George MA, Naranjo Ortiz C, Lustberg MB. HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer. Cancer Medicine. 2025;14(23). doi:10.1002/cam4.71415

BibTeX
@article{Lee2025,
  author = {Lee, Seohyuk and Kahn, Adriana M and Rozenblit, Mariya and George, Mridula A and Naranjo Ortiz, Cristina and Lustberg, Maryam B},
  title = {HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {23},
  doi = {10.1002/cam4.71415}
}
Kostenlos starten →